How Brenda Odera Became Kisumu’s Bridge to HIV Prevention
For Brenda Odera, closing the gender gap in HIV infections in Kenya starts with a conversation. Raised in a community where HIV was widely discussed but its disproportionate impact on women was often overlooked, Odera now spends 40 hours a week as a volunteer “PrEP champion” along the shores of Lake Victoria in Kisumu. Her mission: talk to women and girls about pre-exposure prophylaxis (PrEP) — a medication taken before exposure to HIV to prevent infection — and help them navigate the barriers that keep many from seeking it out.
Kenya has cut its HIV incidence rate by more than 80% in the past decade, yet women aged 15 and older accounted for over half of all new cases in 2024. Odera, working with clinics like the Lumumba Sub-County Hospital, addresses the stigma and privacy concerns that deter women from starting PrEP. Many live in crowded homes where daily pills can be easily discovered, and walking into a clinic carrying medication invites judgment. Odera walks women to the hospital herself, where they can receive long-acting prevention options administered discreetly by clinicians.
Dr. Jared Olwal, who runs the PrEP clinic at Lumumba, says he rarely saw women under 25 before Odera began bridging the gap. Now the partnership has become essential. “They walk away without anybody knowing what they have,” he says of the long-acting regimen. Odera’s work is part of a broader network of community educators and advocates, including Florence Riako Anam, Co-Executive Director of the Global Network of People Living with HIV, who emphasizes that prevention is shifting from a judgment-laden societal tool to an act of self-care.
The effort has drawn attention from global pharma. Daniel O’Day, Chairman and CEO of Gilead Sciences, whose company makes long-acting HIV prevention options, says “transformative scientific innovation can only reach its full potential through strong partnerships” with local communities, governments and health providers. Odera herself hopes to see more women become “champions” like her, loosening the grip of stigma and infection on Kisumu.
What the PrEP Champion Model Reveals About Long-Acting Prevention and Pharma Strategy
The Community Champion as a Structural Fix
Odera’s role is not just a feel-good story — it addresses a real delivery failure. HIV prevention tools exist, but the barriers Elizabeth Bukusi, Chief Research Officer at the Kenya Medical Research Institute, outlines are formidable: biological susceptibility, financial dependence on partners that makes condom negotiation impossible, and crowded living conditions that make pill-taking a public act. A trusted peer who walks a woman to a clinic and stays with her through the process cuts through each of these. Dr. Olwal’s experience — seeing the clinic’s under-25 female attendance rise only after Odera began her work — provides on-the-ground evidence that a human bridge can be as critical as the medicine itself.
Long-Acting Options Shift the Privacy Equation
Daily oral PrEP is effective, but the pill bottle in a one‑room home can spark dangerous questions. An injection or implant given in a clinic, with no visible evidence leaving the building, removes that risk. The article’s emphasis on long‑acting options — and Dr. Olwal’s remark that women leave without anyone knowing — signals a product‑attribute advantage that could dramatically alter uptake among women who cannot afford to be seen using prevention. This is a design‑meets‑context moment: the product’s discreetness matches a deep‑seated social need.
Gilead’s Stake in the Community‑Led Model
Gilead Sciences’ involvement in this story is not accidental. CEO Daniel O’Day frames the company’s progress against HIV as inseparable from partnerships with governments, health organizations and local communities. For Gilead, the community champion model in Kisumu is a proof‑of‑concept for demand generation. If a network of volunteers can convert latent need into actual clinic visits, the commercial payoff — for a product that otherwise might stall at the pharmacy gate — is substantial. Yet the piece leaves unanswered how these volunteer roles are funded and whether they are sustainable without deeper integration into public health budgets.
From Charity to Agency: The Prevention Narrative
Florence Riako Anam’s observation that HIV was once framed as “a disease for bad women” and that prevention was deployed as a societal tool, not a form of self‑care, points to an underappreciated barrier: moral stigma embedded in public health messaging. The shift toward framing PrEP as an act of individual agency — supported by discreet, long‑acting options and delivered through empathetic peers — represents a marketing and policy challenge as much as a medical one. For pharma and health ministries alike, the story suggests that success depends on aligning product innovation with a reworked narrative that meets women where they are, financially and socially.
What Health Providers and Policymakers Can Draw from the Kisumu Approach
- Invest in community health worker cadres: The Odera–Olwal partnership demonstrates that a locally trusted guide can move at‑risk women into care. Health ministries and global funders should allocate specific line items for trained “champions” in HIV prevention programs, not rely solely on volunteer goodwill.
- Integrate long‑acting PrEP into routine clinic workflows with a privacy guarantee: Clinics must design administration protocols — separate rooms, anonymous appointment times — that mirror the discreetness Dr. Olwal describes. Standardizing this practice can reduce the stigma‑driven drop‑off that currently keeps women away from daily pill regimens.
- Pharma should structure demand‑side partnerships with local organizations: Gilead’s quoted commitment to collaboration can be turned into contractual, measurable partnerships with community‑based groups that do the on‑the‑ground education and escort work. This turns a CSR narrative into a scalable distribution strategy.
- Design prevention messaging that centers agency, not blame: Public health campaigns, particularly those targeting women, need to explicitly rebrand PrEP as a private, self‑care choice, drawing on the insight from Anam that historical messaging weakened uptake. Communicators should test framing that resonates with the financial and social realities highlighted by Kenya Medical Research Institute’s Bukusi.
Risk & Opportunity Assessment
| Commercial Risk | Medium | Gilead’s long‑acting PrEP uptake relies on community trust and clinic partnerships. If the volunteer champion model proves unsustainable or competition offers similar discreet options earlier in larger volumes, the early‑mover advantage could erode. |
| Competitive Risk | Low | While Gilead currently holds a strong position with its long‑acting formulation, other pharmaceutical companies are developing comparable injectables and implants. The story notes no imminent competitor in the specific Kisumu context, but the market is not static. |
| Regulatory Risk | Low | Long‑acting PrEP is already approved and integrated into Kenya’s health system; the narrative focuses on access, not regulatory hurdles. No policy shifts are suggested that would immediately disrupt delivery. |
| Reputation Risk | Medium | Any failure in the community‑driven model—such as a privacy breach, adverse event linked to a long‑acting product, or perceived exploitation of volunteers—could damage Gilead’s image as a partner in the HIV fight, consistent with the reputation‑sensitive nature of global health engagements. |
| Technology Disruption | Low | The long‑acting options described are incremental improvements in delivery, not a disruption to the class of PrEP. While they solve a critical real‑world problem, they do not represent a fundamental shift that threatens existing pharmaceutical business models. |
| Commercial Opportunity | High | With women accounting for over half of new HIV infections in Kenya and clear evidence that community navigation drives adoption, Gilead and its partners can expand into a large, underserved segment by replicating the Kisumu model in other high‑burden regions. The CEO’s own words frame this as a frontier for growth. |
Comments 0